Gentamicin/vancomycin

Drug Profile

Gentamicin/vancomycin

Alternative Names: DFA-02; Vancomycin/gentamicin

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dr Reddys Laboratories; Duke Clinical Research Institute
  • Class Aminoglycosides; Antibacterials; Glycopeptides; Peptide antibiotics; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Postoperative infections

Most Recent Events

  • 27 Jul 2017 Dr Reddys Laboratories and CHD Bioscience agree to co-promote and co-develop gentamicin/vancomycin gel in World for prevention of Postoperative infections
  • 27 Jul 2017 Pooled pharmacokinetic, efficacy and adverse events data from two trials in prevention of Postoperative infections released by Dr Reddys Laboratories
  • 27 Jul 2017 Dr Reddys Laboratories plans pivotal phase III trials for Postoperative infections (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top